Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

• the present invention relates to certain aminoquinazolinyl compounds, pharmaceutical compositions containing them, and methods of using them for the treatment of disease states, disorders, and conditions mediated by prolyl
• HIFs Hypoxia- inducible factors
• HIF-a Three forms of HIF-a have been described: HIF-1 a, H IF-2a and HIF-3a (Scheuermann et al., 2007, Methods Enzymol., 435:3- 24). Pairing of a HIFa sub-unit with H IF-1 ⁇ forms a functional heterodimeric protein that subsequently recruits other transcriptional factors such as p300 and CBP (Semenza, 2001 , Trends Mol Med., 7(8):345-50).
• a family of highly conserved oxygen, iron, and 2-oxoglutarate-dependent prolyl hydroxylase (PHD) enzymes mediate the cells response to hypoxia via post- translational modification of HIF (Ivan et al., 2001 , Science, 292:464-68; Jaakkola et al., 2001 , Science, 292:468-72).
• PHD catalyzes the hydroxylation of two conserved proline residues within HIF.
• Von Hippel Lindau (VHL) protein binds selectively to hydroxylated HIF.
• VHL The binding of VHL renders HIF a target for polyubiquitination by the E3 ubiquitin ligase complex and its subsequent degradation by the 26S proteasome (Ke et al., 2006, Mol Pharmacol. 70(5):1469-80; Semenza, Sci STKE., 2007, 407(cm8):1 -3).
• PHD As the affinity of PHD for oxygen is within the physiological range of oxygen and oxygen is a necessary co-factor for the reaction, PHD is inactivated when oxygen tension is reduced. In this way, HIF is rapidly degraded under normoxic conditions but accumulates in cells under hypoxic conditions or when PHD is inhibited.
• PHD1 Four isotypes of PHD have been described: PHD1 , PHD2, PHD3, and PHD4 (Epstein et al., 2001 , Cell, 107:43-54; Kaelin, 2005, Annu Rev Biochem., 74:1 15-28; Schmid et al., 2004, J Cell Mol Med., 8:423-31 ).
• the different isotypes are
• PHD1 is primarily nuclear
• PHD2 is primarily cytoplasmic
• PHD3 appears to be both cytoplasmic and nuclear (Metzen E, et al. 2003, J Cell Sci., 1 16(7):1319-26).
• PHD2 appears to be the predominant HIFa prolyl hydroxylase under normoxic conditions (Ivan et al., 2002. Proc Natl Acad Sci.
• the three isotypes have a high degree of amino-acid homology and the active site of the enzyme is highly conserved.
• the HIF target gene products are involved in a number of physiological and pathophysiological processes including but not limited to: erythropoiesis,
• EPO erythropoietin
• EPO is now implicated in wound healing and angiogenesis as well as the response of tissues to ischemic insult.
• Most of the enzymes involved in anaerobic glycolysis are encoded by HIF target genes and as a result glycolysis is increased in hypoxic tissues (Shaw, 2006, Curr Opin Cell Biol., 18(6):598-608).
• HIF target gene products in this pathway include but are not limited to: glucose transporters such as GLUT-1 (Ebert et al., 1995, J Biol Chem., 270(49):29083-89), enzymes involved in the breakdown of glucose to pyruvate such as hexokinase and phosphoglycerate kinase 1 (Firth et al., 1994, Proc Natl Acad Sci. USA, 91 :6496-6500) as well as lactate dehydrogenase (Firth et al., supra). HIF target gene products are also involved in the regulation of cellular metabolism.
• pyruvate dehydrogenase kinase-1 is a target HIF gene product and regulates the entry of pyruvate into the Kreb's cycle by reducing the activity of pyruvate dehydrogenase by phosphorylation (Kim et al ., 2006, Cell Metab., 3:177-85; Papandreou et al., 2006, Cell Metab., 3:187-197).
• H IF target gene products are also involved in angiogenesis.
• VEGF vascular endothelial growth factor
• VEGF vascular endothelial growth factor
• HIF target gene products also function in the regulation of vascular tone and include heme oxygenase-1 (Lee et al., 1997, J Biol Chem., 272(9):5375-81 ).
• a number of HIF regulated gene products such as platelet- derived growth factor (PDGF) (Yoshida et al., 2006, J Neurooncol., 76(1 ):13-21 ), vascular endothelial growth factor (Breen, 2007, J Cell Biochem., 102(6):1358-67) and EPO (Arcasoy, supra) also function in the coordinated response to wound healing.
• PDGF platelet- derived growth factor
• Targeted disruption of the prolyl hydroxylase (PHD) enzyme activity by small molecules has potential utility in the treatment of disorders of oxygen sensing and distribution.
• disorders of oxygen sensing and distribution examples include but are not limited to: anemia; sickle cell anemia; peripheral vascular disease; coronary artery disease; heart failure; protection of tissue from ischemia in conditions such as myocardial ischemia, myocardial infarction and stroke; preservation of organs for transplant; treatment of tissue ischemia by regulating and/or restoring blood flow, oxygen delivery and/or energy utilization; acceleration of wound healing particularly in diabetic and aged patients; treatment of burns; treatment of infection; bone healing, and bone growth.
• targeted disruption of PHD is expected to have utility in treating metabolic disorders such as diabetes, obesity, ulcerative colitis, inflammatory bowel disease and related disorders such as Crohn's disease.
• metabolic disorders such as diabetes, obesity, ulcerative colitis, inflammatory bowel disease and related disorders such as Crohn's disease.
• HIF has been shown to be the primary transcriptional factor that leads to increased erythropoietin production under conditions of hypoxia (Wang et al., 1993, supra). While treatment with recombinant human erythropoietin has been demonstrated to be an effective method of treating anemia, small molecule mediated PHD inhibition can be expected to offer advantages over treatment with
• HIF gene products are necessary for hematopoesis and regulation of these factors increases the efficiency of hematopoesis.
• HIF target gene products that are critical for
• hematopoesis include: transferrin (Rolfs et al., 1997, J Biol Chem., 272(32):20055- 62), transferrin receptor (Lok et al., 1999, J Biol Chem., 274(34):24147-52; Tacchini et al., 1999, J Biol Chem., 274(34):24142-46) and ceruloplasmin (Mukhopadhyay et al., 2000, J Biol Chem., 275(28):21048-54).
• Hepcidin expression is also suppressed by HIF (Peyssonnaux et al ., 2007, J Clin Invest., 1 17(7):1926-32) and small molecule inhibitors of PHD have been shown to reduce hepcidin production (Braliou et al., 2008, J Hepatol., 48:801 -10).
• Hepcidin is a negative regulator of the availability of the iron that is necessary for hematopoesis, so a reduction in hepcidin production is expected to be beneficial to the treatment of anemia.
• PHD inhibition may also be useful when used in conjunction with other treatments for anemia including iron supplementation and/or exogenous erythropoietin.
• PHD inhibitors increase the expression of genes that lead to changes in metabolism that are beneficial under ischemic conditions (Semenza, 2007, Biochem J., 405:1 -9). Many of the genes encoding enzymes involved in anaerobic glycolysis are regulated by HIF and glycolysis is increased by inhibiting PHD (Shaw, supra).
• HIF target genes in this pathway include but are not limited to: GLUT-1 (Ebert et al., supra), hexokinase, phosphoglycerate kinase 1 , lactate dehydrogenase (Firth et al., supra), pyruvate dehydrogenase kinase-1 (Kim et al., supra; Papandreou et al., supra). Pyruvate dehydrogenase kinase-1 suppresses the entry of pyruvate into the Kreb's cycle.
• HIF mediates a switch in the expression of the cytochromes involved in electron transport in the mitochondria (Fukuda et al., 2007, Ce//,129(1 ):1 1 1 -22). This change in the cytochrome composition optimizes the efficiency in ATP production under hypoxic conditions and reduces the production of injurious oxidative phosphorylation by-products such as hydrogen peroxide and superoxide. With prolonged exposure to hypoxia, HIF drives autophagy of the mitochondria resulting in a reduction in their number (Zhang H et al., 2008, J Biol Chem. 283: 10892-10903). This adaptation to chronic hypoxia reduces the production of hydrogen peroxide and superoxide while the cell relies on glycolysis to produce energy.
• a further adaptive response produced by HIF elevation is up-regulation of cell survival factors.
• IGF Insulin-like growth factor
• IGF-binding protein 2 and 3 a further adaptive response produced by HIF elevation.
• Overall accumulation of HIF under hypoxic conditions governs an adaptive up-regulation of glycolysis, a reduction in oxidative phosphorylation resulting in a reduction in the production of hydrogen peroxide and superoxide, optimization of oxidative phosphorylation protecting cells against ischemic damage.
• PHD inhibitors are expected to be useful in organ and tissue transplant preservation (Bernhardt et al ., 2007, Methods Enzymol., 435:221 -45). While benefit may be achieved by administering PHD inhibitors before harvesting organs for transplant, administration of an inhibitor to the organ/tissue after harvest, either in storage (e.g., cardioplegia solution) or post-transplant, may also be of therapeutic benefit.
• PHD inhibitors are expected to be effective in preserving tissue from regional ischemia and/or hypoxia. This includes ischemia/hypoxia associated with inter alia: angina, myocardial ischemia, stroke, ischemia of skeletal muscle. There are a number of lines of experimental evidence that support the concept that PHD inhibition and subsequent elevation of H IF as a useful method for preserving ischemic tissue. Recently, ischemic pre-conditioning has been demonstrated to be a HIF-dependent phenomenon (Cai et al., 2008, Cardiovasc Res., 77(3):463-70).
• Ischemic pre-conditioning is a well known phenomenon whereby short periods of hypoxia and/or ischemia protect tissue from subsequent longer periods of ischemia (Murry et al., 1986, Circulation, 74(5):1 124-36; Das et al., 2008, IUBMB Life, 60(4):199-203). Ischemic pre-conditioning is known to occur in humans as well as experimental animals (Darling et al., 2007, Basic Res Cardiol., 102(3):274-8; Kojima I et al ., 2007, J Am Soc Nephrol., 18:1218-26).
• pre- conditioning is best known for its protective effects in the heart, it also applies to other tissues including but not limited to: liver, skeletal muscle, liver, lung, kidney, intestine and brain (Pasupathy et al., 2005, Eur J Vase Endovasc Surg., 29:106-15; Mallick et al., 2004, Dig Dis Sci., 49(9):1359-77).
• HIF up-regulation has also been shown to protect the heart of diabetic mice, where outcomes are generally worse (Natarajan et al., 2008, J Cardiovasc Pharmacol., 51 (2):178-187).
• the tissue protective effects may also be observed in Buerger's disease, Raynaud's disease, and acrocyanosis.
• PHD inhibition produces a pseudohypoxia associated with the hypoxic response being initiated through H IF but with tissue oxygenation remaining normal.
• the alteration of metabolism produced by PHD inhibition can also be expected to provide a treatment paradigm for diabetes, obesity and related disorders, including co-morbidities.
• WO2004/052284 June 24, 2004
• WO2004/052285 June 24, 2004
• db/db mouse and Zucker fa/fa rat models were lowering of: blood glucose concentration, fat mass in both abdominal and visceral fat pads, hemoglobin A1 c, plasma triglycerides, body weight as well as changes in established disease bio-markers such as increases in the levels of adrenomedullin and leptin.
• Leptin is a known HIF target gene product (Grosfeld et al., 2002, J Biol Chem., 277(45):42953-57).
• PHD inhibition Gene products involved in the metabolism in fat cells were demonstrated to be regulated by PHD inhibition in a HIF-dependent fashion (Intl. Pat. Appl. Publ . WO2004/052285, supra). These include apolipoprotein A-IV, acyl CoA thioesterase, carnitine acetyl transferase, and insulin-like growth factor binding protein (IGFBP)-1 . PHD inhibitors are expected to be therapeutically useful as stimulants of vasculogenesis, angiogenesis, and arteriogenesis.
• VEGF receptor activators While administration of various forms of VEGF receptor activators are potent stimuli for angiogenesis, the blood vessel resulting from this potential form of therapy are leaky. This is considered to limit the potentially utility of VEGF for the treatment of disorders of oxygen delivery. The increased expression of a single angiogenic factor may not be sufficient for functional vascularization (Semenza, 2007, supra).
• PHD inhibition offers a potential advantage over other such angiogenic therapies in that it stimulates a controlled expression of multiple angiogenic growth factors in a HIF-dependent fashion including but not limited to: placental growth factor (PLGF), angiopoietin-1 (ANGPT1 ), angiopoietin-2 (ANGPT2), platelet-derived growth factor beta (PDGFB) (Carmeliet, 2004, J Intern Med., 255:538-61 ; Kelly et al., 2003, Circ Res., 93:1074- 81 ) and stromal cell derived factor 1 (SDF-1 ) (Ceradini et al., 2004, Nat Med., 10(8):858-64).
• PLGF placental growth factor
• ANGPT1 angiopoietin-1
• ANGPT2 angiopoietin-2
• PDGFB platelet-derived growth factor beta
• SDF-1 stromal cell derived factor 1
• angiopoietin-1 produces leakage- resistant blood vessels, in contrast to the vessels produced by administration of VEGF alone (Thurston et al., 1999, Science, 286:251 1 -14; Thurston et al., 2000, Nat Med., 6(4):460-3; Elson et al., 2001 , Genes Dev., 15(19):2520-32).
• Stromal cell derived factor 1 (SDF-1 ) has been shown to be critical to the process of recruiting endothelial progenitor cells to the sites of tissue injury. SDF-1 expression increased the adhesion, migration and homing of circulating CXCR4-positive progenitor cells to ischemic tissue.
• Placental growth factor also a HIF target gene, has been show to play a critical role in angiogenesis in ischemic tissue (Carmeliet, 2004, J Intern Med., 255(5):538-61 ; Luttun et al ., 2002, Ann N Y Acad Sci., 979:80-93).
• PHD inhibitors will be effective in stimulating angiogenesis in the setting of tissue ischemia, particularly muscle ischemia. It is expected that therapeutic angiogenesis produced by PHD inhibitors will be useful in restoring blood flow to tissues and therefore the treatment of disease including but not restricted to angina pectoris, myocardial ischemia and infarction, peripheral ischemic disease, claudication, gastric and duodenal ulcers, ulcerative colitis, and inflammatory bowel disease.
• PHD and HIF play a central role in tissue repair and regeneration including healing of wounds and ulcers.
• Recent studies have demonstrated that an increased expression of all three PHDs at wound sites in aged mice with a resulting reduction in HIF accumulation (Chang et al., supra).
• elevation of HIF in aged mice by administering desferrioxamine increased the degree of wound healing back to levels observed in young mice.
• HIF elevation was suppressed compared to non-diabetic litter mates (Mace et al ., 2007, Wound Repair Regen., 15(5):636-45).
• HIF target genes such as VEGF, Nos2, and Hmoxl
• the beneficial effect of PHD inhibition is not restricted to the skin and small molecule inhibitors of PHD have recently been demonstrated to provide benefit in a mouse model of colitis (Robinson et al., 2008, Gastroenterology, 134(1 ):145-55).
• PHD inhibition resulting in accumulation of HIF is expected to act by at least four mechanisms to contribute to accelerated and more complete healing of wounds: 1 ) protection of tissue jeopardized by hypoxia and/or ischemia, 2) stimulation of angiogenesis to establish or restore appropriate blood flow to the site, 3) recruitment of endothelial progenitor cells to wound sites, 4) stimulation of the release of growth factors that specifically stimulate healing and regeneration.
• PDGF platelet-derived growth factor
• RegranexTM Recombinant human platelet-derived growth factor
• Becaplermin has been shown to be effective in accelerating wound healing in diabetic patients (Steed, 2006, Plast Reconstr Surg., 1 17(7 Suppl):143S-149S; Nagai et al., 2002, Expert Opin Biol Ther., 2(2):21 1 -8).
• PHD inhibition is expected to increase the expression of endogenous PDGF and produce a similar or more beneficial effect to those produced with becaplermin alone.
• Studies in animals have shown that topical application of PDGF results in increased wound DNA, protein, and hydroxyproline amounts; formation of thicker granulation and epidermal tissue; and increased cellular repopulation of wound sites.
• PDGF exerts a local effect on enhancing the formation of new connective tissue.
• the effectiveness of PHD inhibition is expected to be greater than that produced by becaplermin due to the additional tissue protective and pro-angiogenic effects mediated by HIF.
• the beneficial effects of inhibition of PHD are expected to extend not only to accelerated wound healing in the skin and colon but also to the healing of other tissue damage including but not limited to gastrointestinal ulcers, skin graft replacements, burns, chronic wounds and frost bite.
• Stem cells and progenitor cells are found in hypoxic niches within the body and hypoxia regulates their differentiation and cell fate (Simon et al., 2008, Nat Rev Mol Cell Biol., 9:285-96).
• PHD inhibitors may be useful to maintain stem cells and progenitor cells in a pluripotent state and to drive differentiation to desired cell types.
• Stem cells may be useful in culturing and expanding stem cell populations and may hold cells in a pluripotent state while hormones and other factors are administered to the cells to influence the differentiation and cell fate.
• a further use of PHD inhibitors in the area of stem cell and progenitor cell therapeutics relates to the use of PHD inhibitors to condition these cells to withstand the process of implantation into the body and to generate an appropriate response to the body to make the stem cell and progenitor cell implantation viable (Hu et al., 2008, J Thorac Cardiovasc Surg., 135(4):799-808). More specifically PHD inhibitors may facilitate the integration of stem cells and draw in an appropriate blood supply to sustain the stem cells once they are integrated. This blood vessel formation will also function to carry hormones and other factors released from these cells to the rest of the body.
• PHD inhibitors may also be useful in the treatment of infection (Peyssonnaux et al., 2005, J Invest Dermatol., 1 15(7):1806-15; Peyssonnaux et al., 2008 J Invest Dermatol., 2008 Aug;128(8):1964-8). HIF elevation has been demonstrated to increase the innate immune response to infection in phagocytes and in
• Phagocytes in which HIF is elevated show increased bacteriacidal activity, increased nitric oxide production and increased expressed of the antibacterial peptide cathelicidin. These effects may also be useful in treating infection from burns.
• HIF has also been shown to be involved in bone growth and healing (Pfander D et al ., 2003 J Cell Sci., 1 16(Pt 9):1819-26., Wang et al., 2007 J Clin Invest, 17(6):1616-26.) and may therefore be used to heal or prevent fractures.
• HIF stimulates of glycolysis to provide energy to allow the synthesis of extracellular matrix of the epiphyseal chondrocytes under a hypoxic environment.
• HIF also plays a role in driving the release of VEGF and angiogenesis in bone healing process.
• the growth of blood vessels into growing or healing bone can be the rate limiting step in the process.
• the present invention is directed to compounds which are useful inhibitors of PHD.
• the compounds of the present invention are of general Formula
• n 0-3
• R 1 is a member independently selected from the group consisting of halo, -O-R c , -Ci_
• R a is H and R b is benzyl optionally substituted with -Ci -4 alkyl, or R a and R b are taken together with the nitrogen to which they are attached to form a piperidine ring; R c is cyclohexyl, phenyl optionally substituted with one or more R d members;
• R d is a member independently selected from the group consisting of -H, halo,
• R 2 is a member independently selected from the group consisting of -H, and -Ci_ 4 alkyl,
• R 3 is a member independently selected from the group consisting of -H, -Ci -4 alkyl optionally substituted with -OCH 3 or -N(Ci -4 alkyl) 2 , cyano, -SO2CH3,
• n 0-1 ;
• R 2 and R 3 can be taken together with the nitrogen to which they are attached to form a 4 to 7 membered heterocycloalkyi ring optionally containing O, N, S optionally substituted with -OH, cyano, halo, -N-C(O)Ci -4 alkyl, and -Ci -4 alkyl;
• the invention also relates to pharmaceutically acceptable salts
• the compound of Formula (I) is a compound selected from those species described or exemplified in the detailed description below.
• the invention relates to pharmaceutical
• compositions each comprising: (a) an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite thereof; and (b) a pharmaceutically acceptable excipient.
• the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by a prolyl hydroxylase enzyme activity, comprising administering to the subject in need of such treatment an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite thereof.
• the disease, disorder, or medical condition is selected from: anemia, vascular disorders, metabolic disorders, and wound healing.
• alkyl refers to a straight- or branched-chain alkyl group having from
• alkyl groups include methyl (Me, which also may be structurally depicted by the symbol, 7"), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
• alkenyl refers to a straight- or branched-chain alkenyl group having from 2 to 12 carbon atoms in the chain. (The double bond of the alkenyl group is formed by two sp 2 hybridized carbon atoms.)
• Illustrative alkenyl groups include prop- 2-enyl, but-2-enyl, but-3-enyl, 2-methylprop-2-enyl, hex-2-enyl, and the like.
• alkynyl refers to a straight- or branched-chain alkynyl group having from 2 to 12 carbon atoms in the chain. (The triple bond of the alkynyl group is formed by two sp hybridized carbon atoms.)
• Illustrative alkynyl groups include prop- 2-ynyl, but-2-ynyl, but-3-ynyl, 2-methylbut-2-ynyl, hex-2-ynyl, and the like.
• cycloalkyl refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle.
• Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:
• heterocycloalkyl refers to a monocyclic ring structure that is saturated or partially saturated, monocyclic, fused polycyclic, and has from 3 to 8 ring atoms per ring structure selected from carbon atoms and up to two heteroatoms selected from nitrogen, oxygen, and sulfur.
• the ring structure may optionally contain up to two oxo groups on sulfur ring members.
• Illustrative entities, in the form of properly bonded moieties include:
• heteroaryl refers to a monocyclic, fused bicyclic, or fused polycyclic aromatic heterocycle (ring structure having ring atoms selected from carbon atoms and up to four heteroatoms selected from nitrogen, oxygen, and sulfur) having from 3 to 12 ring atoms per heterocycle.
• heteroaryl groups include the following entities, in the form of properly bonded moieties:
• heterocycloalkyi, and heteroaryl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.
• halogen represents chlorine, fluorine, bromine or iodine.
• halo represents chloro, fluoro, bromo or iodo.
• substituted means that the specified group or moiety bears one or more substituents.
• unsubstituted means that the specified group bears no substituents.
• optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents.
• substituted is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.
• any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
• compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula.
• any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
• any formula given herein is intended to refer also to hydrates, solvates, and polymorphs of such compounds, and mixtures thereof, even if such forms are not listed explicitly.
• Certain compounds of Formula (I) or pharmaceutically acceptable salts of compounds of Formula (I) may be obtained as solvates.
• Solvates include those formed from the interaction or complexation of compounds of the invention with one or more solvents, either in solution or as a solid or crystalline form.
• the solvent is water and then the solvates are hydrates.
• certain crystalline forms of compounds of Formula (I) or pharmaceutically acceptable salts of compounds of Formula (I) may be obtained as co-crystals.
• compounds of Formula (I) were obtained in a crystalline form.
• crystalline forms of compounds of Formula (I) were cubic in nature.
• pharmaceutically acceptable salts of compounds of Formula (I) were obtained in a crystalline form.
• compounds of Formula (I) were obtained in one of several polymorphic forms, as a mixture of crystalline forms, as a polymorphic form, or as an amorphous form. In other embodiments, compounds of Formula (I) convert in solution between one or more crystalline forms and/or polymorphic forms.
• references to a chemical entity herein stands for a reference to any one of: (a) the actually recited form of such chemical entity, and (b) any of the forms of such chemical entity in the medium in which the compound is being considered when named.
• a compound such as R-COOH for example, reference herein to a compound such as R-COOH,
• R-COOH (S ) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation
• R-COOH(soi) refers to the undissociated form of the compound in a solvent
• R- COO " (soi) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R-COOH, from a salt thereof, or from any other entity that yields R-COO " upon dissociation in the medium being considered.
• an expression such as "exposing an entity to compound of formula R- COOH” refers to the exposure of such entity to the form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such exposure takes place.
• an expression such as "reacting an entity with a compound of formula R-COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such reacting takes place.
• a zwitterionic compound is encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form.
• Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard lUPAC-endorsed names that are well known and part of standard sets of defined scientific names.
• the name zwitterion is assigned the name identification CHEBI:27369 by the Chemical Entities of Biological Inerest (ChEBI) dictionary of molecular entities.
• a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign.
• aminoethanoic acid (the amino acid glycine) has the formula
• any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
• Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
• isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 1 1 C, 13 C, 14 C, 15 N, 18 O, 17 0, 31 P, 32 P, 35 S, 18 F, 36 CI, 125 l, respectively.
• Such isotopically labeled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
• PET positron emission tomography
• SPECT single-photon emission computed tomography
• an 18 F or 1 1 C labeled compound may be particularly preferred for PET or SPECT studies.
• substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
• Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
• S 1 exa mpie is one of Si and S 2
• S 2 exa mpie is one of S3 and S 4 " is accordingly used herein for the sake of brevity, but not by way of linnitation.
• the foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein.
• embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof.
• substituent S exa mpie is one of Si , S 2 , and S 3
• this listing refers to embodiments of this invention for which S ex ampie is Si ; S ex ampie is S2; S ex ampie is S3; Sexampie is one of Si and
• S exa mpie is any equivalent of each one of these choices.
• S exa mpie is one of Si , S 2 , and S 3 " is accordingly used herein for the sake of brevity, but not by way of limitation.
• the foregoing second example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein.
• substituents is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to J including i and j, is independently realized.
• the term d -3 refers independently to embodiments that have one carbon member (Ci ), embodiments that have two carbon members (C2), and embodiments that have three carbon members (C3).
• C n-m alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n ⁇ N ⁇ m, with m > n.
• any disubstituent referred to herein is meant to encompass the various attachment possibilities when more than one of such possibilities are allowed.
• reference to disubstituent -A-B-, where A ⁇ B, refers herein to such disubstituent with A attached to a first substituted member and B attached to a second substituted member, and it also refers to such disubstituent with A attached to the second substituted member and B attached to the first substituted member.
• the present invention includes the use of compounds of Formula (I),
• the instant invention also includes methods of making such a compound, pharmaceutical composition, pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, and pharmaceutically active metabolites thereof.
• R 1 is independently bromo, chloro, fluoro, methyl, isopropyl, cyclohexyl, cyclohexyloxy, phenyl, 2-methylphenyl, benzyl, phenoxy, 4-chlorophenoxy, 2,6-dimethyl-phenoxy, piperidinyl, and (2,6-dimethylbenzyl)amino.
• n 1 .
• n is 2.
• n 3.
• R a is -H and R b is 2,6-dimethylbenzyl.
• R a and R b can be taken together with the nitrogen to which they are attached to form a piperidine ring.
• R c can be phenyl, cyclohexyl, 4- chlorophenyl, or 2,6-dimethyl-phenyl.
• R d can independently be -H, chloro, and -
• R 2 is -H and R 3 can independently be -H, cyano, methyl, ethyl, propyl, tertbutyl, cyclopropyl, cyclopropylmethyl,
• R 2 can be methyl, ethyl, propyl, or butyl.
• R 3 can be methyl, ethyl, propyl, butyl, tertbutyl, 2-methoxyethyl, 2-methoxy-1 -methyl-ethyl or diethylamino-ethyl.
• R 2 and R 3 can be taken together with the nitrogen to which they are attached to form pyrrolidine, piperidine, 4-methyl-1 ,4- diazepane, thiomorpholine, 4-hydroxypiperidine, morpholine, 4-acetamidopiperidine, 4-cyanopiperidine, 4-fluoropiperidine, azepane, or 4-isopropylpiperidine.
• the compound of Formula (I) is selected from the group consisting of:
• the invention includes also pharmaceutically acceptable salts of the compounds of Formula (I), preferably of those described above and of the specific compounds exemplified herein, and methods of treatment using such salts.
• a “pharmaceutically acceptable salt” is intended to mean a salt of a free acid or base of a compound represented by Formula (I) that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, G.S. Paulekuhn, et al., "Trends in Active Pharmaceutical Ingredient Salt Selection based on Analysis of the Orange Book Database", J. Med. Chem., 2007, 50:6665-72, S.M. Berge, et al., “Pharmaceutical Salts”, J Pharm Sci., 1977, 66:1 -19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002.
• Examples of pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
• a compound of Formula (I) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
• Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates,
• dihydrogenphosphates metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1 ,4-dioates, hexyne-1 ,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, ⁇ -hydroxybutyrates, glycolates, tartrates, methane-sulfonates
• the desired pharmaceutically acceptable salt may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an inorganic acid, such as hydrochloric acid,
• the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
• an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
• suitable salts include organic salts derived from amino acids, such as N-methyl-D-glucamine, lysine, choline, glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
• amino acids such as N-methyl-D-glucamine, lysine, choline, glycine and arginine
• ammonia carbonates, bicarbonates, primary, secondary, and tertiary amines
• cyclic amines such as tromethamine, benzylamines, pyrrolidines, piperidine, morpholine, and piperazine
• inorganic salts derived
• Exemplary prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues, covalently joined through an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of Formula (I).
• amino acid residues include the twenty naturally occurring amino acids, commonly designated by three letter symbols, as well as 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.
• prodrugs may be produced, for instance, by derivatizing free carboxyl groups of structures of Formula (I) as amides or alkyl esters.
• amides include those derived from ammonia, primary C h alky! amines and secondary di(Ci-6alkyl) amines. Secondary amines include 5- or 6-membered heterocycloalkyi or heteroaryl ring moieties. Examples of amides include those that are derived from ammonia, C h alky! primary amines, and di(Ci- 2 alkyl)amines.
• esters of the invention include Ci -7 alkyl, C 5-7 cycloalkyl, phenyl, and phenyl(Ci-6alkyl) esters.
• Preferred esters include methyl esters.
• Prodrugs may also be prepared by derivatizing free hydroxy groups using groups including
• phosphoryloxymethyloxycarbonyls following procedures such as those outlined in Fleisher et al., Adv. Drug Delivery Rev. 1996, 19, 1 15-130.
• Carbamate derivatives of hydroxy and amino groups may also yield prodrugs.
• Carbonate derivatives, sulfonate esters, and sulfate esters of hydroxy groups may also provide prodrugs.
• Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers, wherein the acyl group may be an alkyl ester, optionally substituted with one or more ether, amine, or carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, is also useful to yield prodrugs.
• Prodrugs of this type may be prepared as described in Robinson et al., J Med Chem. 1996, 39 (1 ), 10-18. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including ether, amine, and carboxylic acid functionalities.
• the present invention also relates to pharmaceutically active metabolites of the compounds of Formula (I), which may also be used in the methods of the invention.
• a "pharmaceutically active metabolite” means a pharmacologically active product of metabolism in the body of a compound of Formula (I) or salt thereof.
• Prodrugs and active metabolites of a compound may be determined using routine techniques known or available in the art. See, e.g., Bertolini, et al., J Med Chem. 1997, 40, 201 1 -2016; Shan, et a ⁇ ., J Pharm Sci. 1997, 86 (7), 765-767; Bagshawe, Drug Dev Res. 1995, 34, 220-230; Bodor, Adv Drug Res. 1984, 13, 224-331 ;
• modulators include both inhibitors and activators, where “inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize or down-regulate PHD expression or activity, and “activators” are compounds that increase, activate, facilitate, sensitize, or up-regulate PHD expression or activity.
• Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition mediated through modulation of PHD activity.
• subject refers to a mammalian patient in need of such treatment, such as a human.
• the invention relates to methods of using the compounds described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition mediated by Prolyl Hydroxylase, such as: Anemia, vascular disorders, metabolic disorders, and wound healing. Symptoms or disease states are intended to be included within the scope of "medical conditions, disorders, or diseases.”
• hypoxic disorders refers to a condition where there is an insufficient level of oxygen provided in the blood or to tissues and organs. Hypoxic disorders can occur through a variety of mechanisms including where there is an insufficient capacity of the blood to carry oxygen (i.e. anemia), where there is an inadequate flow of blood to the tissue and/or organ caused by either heart failure or blockage of blood vessels and/or arteries (i.e. ischemia), where there is reduced barometric pressure (i.e. elevation sickness at high altitudes), or where dysfunctional cells are unable to properly make use of oxygen (i.e. hystotoxic conditions). Accordingly, one of skill in the art would readily appreciate the present invention to be useful in the treatment of a variety of hypoxic conditions including anemia, heart failure, coronary artery disease, thromboembolism, stroke, angina and the like.
• molecules of the present invention are useful in the treatment or prevention of anemia comprising treatment of anemic conditions associated with chronic kidney disease, polycystic kidney disease, aplastic anemia, autoimmune hemolytic anemia, bone marrow transplantation anemia, Churg-Strauss syndrome, Diamond Blackfan anemia, Fanconi's anemia, Felty syndrome, graft versus host disease, hematopoietic stem cell transplantation, hemolytic uremic syndrome, myelodysplastic syndrome, nocturnal paroxysmal hemoglobinuria, osteomyelofibrosis, pancytopenia, pure red-cell aplasia, purpura Schoenlein-
• Henoch Henoch, refractory anemia with excess of blasts, rheumatoid arthritis, Shwachman syndrome, sickle cell disease, thalassemia major, thalassemia minor,
• thrombocytopenic purpura anemic or non-anemic patients undergoing surgery, anemia associated with or secondary to trauma, sideroblastic anemia, anemic secondary to other treatment including: reverse transcriptase inhibitors to treat HIV, corticosteroid hormones, cyclic cisplatin or non-cisplatin-containing
• chemotherapeutics include vinca alkaloids, mitotic inhibitors, topoisomerase II inhibitors, anthracyclines, alkylating agents, particularly anemia secondary to inflammatory, aging and/or chronic diseases.
• PHD inhibition may also be used to treat symptoms of anemia including chronic fatigue, pallor and dizziness.
• molecules of the present invention are useful for the treatment or prevention of diseases of metabolic disorders, including but not limited to diabetes and obesity.
• molecules of the present invention are useful for the treatment or prevention of vascular disorders. These include but are not limited to hypoxic or wound healing related diseases requiring pro-angiogenic mediators for vasculogenesis, angiogenesis, and arteriogenesis
• an effective amount of a pharmaceutical agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition.
• An "effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in patients in need of such treatment for the designated disease, disorder, or condition.
• Effective amounts or doses of the compounds of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the compound, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
• An example of a dose is in the range of from about 0.001 to about 200 mg of compound per kg of subject's body weight per day, preferably about 0.05 to 100 mg/kg/day, or about 1 to 35 mg/kg/day, in single or divided dosage units (e.g., BID, TID, QID).
• a suitable dosage amount is from about 0.05 to about 7 g/day, or about 0.2 to about 2.5 g/day.
• the dose may be adjusted for preventative or maintenance treatment.
• the dosage or the frequency of administration, or both may be reduced as a function of the symptoms, to a level at which the desired therapeutic or
• prophylactic effect is maintained.
• treatment may cease.
• Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
• the agents of the invention may be used in combination with additional active ingredients in the treatment of the above conditions.
• the additional compounds may be co-administered separately with an agent of Formula (I) or included with such an agent as an additional active ingredient in a pharmaceutical composition according to the invention.
• additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases mediated by PHD enzyme or that are active against another targets associated with the particular condition, disorder, or disease, such as an alternate PHD modulator.
• the combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of a compound according to the invention), decrease one or more side effects, or decrease the required dose of the compound according to the invention.
• a pharmaceutical composition of the invention comprises: (a) an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically active metabolite thereof; and (b) a pharmaceutically acceptable excipient.
• a "pharmaceutically acceptable excipient” refers to a substance that is nontoxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a compound of the invention and that is compatible therewith.
• excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
• compositions containing one or more dosage units of the compounds of the invention may be prepared using suitable pharmaceutical excipients and compounding techniques now or later known or available to those skilled in the art.
• the compositions may be administered in the inventive methods by oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
• the preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories.
• the compositions are formulated for intravenous infusion, topical administration, or oral administration.
• a preferred mode of use of the invention is local administration of PHD inhibitors particularly to sites where tissue has become or has been made ischemic. This may be achieved via a specialized catheter, angioplasty balloon or stent placement balloon.
• the compounds of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension.
• the compounds may be formulated to yield a dosage of, e.g., from about 0.05 to about 100 mg/kg daily, or from about 0.05 to about 35 mg/kg daily, or from about 0.1 to about 10 mg/kg daily.
• Oral tablets may include a compound according to the invention mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
• suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
• Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
• Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are suitable disintegrating agents.
• Binding agents may include starch and gelatin.
• the lubricating agent if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
• Capsules for oral administration include hard and soft gelatin capsules.
• compounds of the invention may be mixed with a solid, semi-solid, or liquid diluent.
• Soft gelatin capsules may be prepared by mixing the compound of the invention with water, an oil such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
• Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
• suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate
• the active agents of this invention may also be administered by non-oral routes.
• the compositions may be formulated for rectal administration as a suppository.
• parenteral use including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the compounds of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
• Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
• Such forms will be presented in unit- dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre- concentrate that can be used to prepare an injectable formulation.
• Illustrative infusion doses may range from about 1 to 1000 g/kg/minute of compound, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
• the compounds may be mixed with a
• compositions of the invention at a concentration of about 0.1 % to about 10% of drug to vehicle.
• examples include lotions, creams, ointments and the like and can be formulated by known methods.
• Another mode of administering the compounds of the invention may utilize a patch formulation to affect transdermal delivery.
• Compounds of the invention may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
• reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0 °C and the reflux temperature of the solvent. Reactions may also be conducted in sealed pressure vessels above the normal reflux temperature of the solvent.
• Ether intermediates of formula (II) are prepared according to Scheme B, where HAL is F, CI.
• Commercially available appropriately substituted halo-nitro- benzenes of formula (X) are allowed to react with substituted phenols (XI) in the presence of a base such as potassium carbonate, in a solvent such as DMSO, DMF, DMA, and the like, at temperatures between room temperature and the reflux temperature of the solvent, providing nitro intermediates of formula (XII).
• Reduction of the nitro group employing methods known to one skilled in the art, for example zinc powder in the presence of a saturated aqueous solution of NH CI in a solvent such as acetone, and the like, affords aniline intermediates of formula (II).
• Amino intermediates of formula (III) may be prepared similarly to the methods utilized for the ether intermediates as described above, by replacing phenols with substituted alkyl amines, heterocycloalkyl amines and aryl amines of formula (XIII).
• reaction mixtures were magnetically stirred at room temperature (rt). Where solutions were “dried,” they were generally dried over a drying agent such as Na2SO 4 or MgSO 4 . Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure.
• Thin-layer chromatography was performed using Merck silica gel 60 F 2 5 4 2.5 cm x 7.5 cm 250 ⁇ or 5.0 cm x 10.0 cm 250 ⁇ pre-coated silica gel plates.
• Preparative thin-layer chromatography was performed using EM Science silica gel 60 F 2 5 4 20 cm x 20 cm 0.5 mm pre-coated plates with a 20 cm x 4 cm concentrating zone.
• Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX spectrometers.
• the format of the 1 H NMR data below is: chemical shift in ppm downfield of the tetramethylsilane reference (apparent multiplicity, coupling constant J in Hz, integration).
• Example 1 1 -[4-Amino-6-(2,6-dimethyl-phenoxy)-7-fluoro-quinazolin-2-yl]-1 H- pyrazole-4-carboxylic acid.
• Step A Preparation of 3-fluoro-4-(2,6-dimethyl-phenoxy)aniline.
• Solid 2,6- dimethylphenol (42.4 g, 346 mmol) was added in portions to a stirred mixture of 3,4- difluoronitrobenzene (50.0 g, 314 mmol), K 2 CO 3 (65.0 g, 138 mmol), and DMSO (500 ml_).
• the mixture was heated to 80 °C for 8 h and then allowed to cool to rt. The mixture was poured into ice water, and the resulting precipitate was collected and dried.
• Step B Preparation of 1 -(4-(2,6-dimethylphenoxy)-3-fluorophenyl)-3- ethoxycarbonylthiourea.
• a mixture of 3-fluoro-4-(2,6-dimethyl-phenoxy)aniline (15.4 g, 66.6 mmol) and DCM (250 mL) was cooled in an ice bath, then neat ethyl isocyanatoformate (9.61 g, 73.2 mmol) was added over 10 min. The resulting solution was allowed to warm to rt and was maintained for 2 h.
• Step C Preparation of 1 -(6-(2,6-dimethylphenoxy)-7-fluoro-4-oxo-3,4- dihydroquinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid, ethyl ester.
• Step D Preparation of 1 -[4-chloro-6-(2,6-dimethyl-phenoxy)-7-fluoro- quinazolin-2-yl]-1 H-pyrazole-4-carboxylic acid, ethyl ester.
• Step E Preparation of 1 -[4-amino-6-(2,6-dimethyl-phenoxy)-7-fluoro- quinazolin-2-yl]-1 H-pyrazole-4-carboxylic acid, ethyl ester.
• a methanol solution of ammonia (7M, 0.39 mL, 2.7 mmol) was added to a solution of the above 1 -[4-chloro- 6-(2,6-dimethyl-phenoxy)-7-fluoro-quinazolin-2-yl]-1 H-pyrazole-4-carboxylic acid, ethyl ester (120 mg, 0.27 mmol) and THF (2 mL). The mixture was stirred 6 h, then concentrated.
• Step F Preparation of 1 -[4-amino-6-(2,6-dimethyl-phenoxy)-7-fluoro- quinazolin-2-yl]-1 H-pyrazole-4-carboxylic acid.
• a mixture of 1 -[4-amino-6-(2,6- dimethyl-phenoxy)-7-fluoro-quinazolin-2-yl]-1 H-pyrazole-4-carboxylic acid, ethyl ester (65 mg, 0.15 mmol), 1 M aqueous LiOH (1 .5 mL, 1 .5 mmol), and THF (3 mL) was heated to 40 °C for 16 h with rapid stirring.
• Example 2 1 -[6-(2,6-Dimethyl-phenoxy)-7-fluoro-4-methylamino-quinazolin-2-yl]- 1 H-pyrazole-4-carboxylic acid.
• Example 3 1 -[4-Dimethylamino-6-(2,6-dimethyl-phenoxy)-7-fluoro-quinazolin-2-yl]- 1 H-pyrazole-4-carboxylic aci
• Example 4 1 -[6-(2,6-Dimethyl-phenoxy)-7-fluoro-4-piperidin-1 -yl-quinazolin-2-yl]- 1 H-pyrazole-4-carboxylic acid.
• Example 5 1 -[6-(2,6-Dimethyl-phenoxy)-7-fluoro-4-pyrrolidin-1 -yl-quinazolin-2-yl]- 1 H-pyrazole-4-carboxylic aci
• Example 6 1 -[6-(2,6-Dimethyl-phenoxy)-7-fluoro-4-phenylamino-quinazolin-2-yl]- 1 H-pyrazole-4-carboxylic acid.
• Example 7 1 -[4-(2-Chloro-phenylamino)-6-(2,6-dimethyl-phenoxy)-7-fluoro- quinazolin-2-yl]-1 H-pyrazole-4-carbox lic acid.
• Example 8 1 -[6-(2,6-Dimethyl-phenoxy)-7-fluoro-4-propylamino-quinazolin-2-yl]-1 H- pyrazole-4-carboxylic acid.
• Example 9 (rac)-1 -[6-(2,6-Dimethyl-phenoxy)-7-fluoro-4-(2-methoxy-1 -methyl- ethylamino)-quinazolin-2-yl]- -pyrazole-4-carboxylic acid.
• Example 10 1 -[4-(2-Diethylamino-ethylamino)-6-(2,6-dimethyl-phenoxy)-7-fluoro- quinazolin-2-yl]-1 H-pyrazole-4-carboxylic acid.
• Example 1 1 -[6-(2,6-Dimethyl-phenoxy)-4-dibutylamino-7-fluoro-quinazolin-2-yl]- 1 H-pyrazole-4-carboxylic aci
• Example 12 1 -[6-(2,6-Dimethyl-phenoxy)-4-dipropylamino-7-fluoro-quinazolin-2-yl]- 1 H-pyrazole-4-carboxylic aci
• Example 13 1 -(4-((Cyclohexylmethyl)amino)-6-(2,6-dimethylphenoxy)-7- fluoroquinazolin-2-yl)-1 H-pyrazo -4-carboxylic acid.
• Example 14 1 -((4-Cyclopropylamino)-6-(2,6-dimethylphenoxy)-7-fluoroquinazolin-2- yl)-1 H-pyrazole-4-carboxylic acid.
• Example 15 1 -((4-Cyclopropanemethylamino)-6-(2,6-dimethylphenoxy)-7- fluoroquinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 16 1 -(6-(2,6-Dimethylphenoxy)-7-fluoro-4-((tetrahydro-2H-pyran-4- yl)amino)quinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 17 1 -(6-(2,6-Dimethylphenoxy)-7-fluoro-4-(4-methyl-1 ,4-diazepan-1 - yl)quinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 18 1 -(6-(2,6-Dimethylphenoxy)-7-fluoro-4-thiomorpholinoquinazolin-2-yl)- 1 H-pyrazole-4-carboxylic acid.
• Example 19 1 -(6-(2,6-Dimethylphenoxy)-7-fluoro-4-(4-hydroxypiperidin-1 - yl)quinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 20 1 -(6-(2,6-Dimethylphenoxy)-7-fluoro-4-morpholinoquinazolin-2-yl)-1 H- pyrazole-4-carboxylic acid.
• Example 21 1 -(4-(4-Acetamidopiperidin-1 -yl)-6-(2,6-dimethylphenoxy)-7- fluoroquinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 22 1 -(6-Cyclohexyl-4-methylamino-quinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 23 1 -[6-Cyclohexyl-4-(2,6-dimethyl-benzylamino)-quinazolin-2-yl]-1 H- pyrazole-4-carboxylic acid.
• Example 24 1 -(4-Amino-6-cyclohexylquinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 25 1 -(6-Cyclohexyl-4-(pyrrolidin-1 -yl)quinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 26 1 -(6-Cyclohexyl-4-(piperidin-1 -yl)quinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 27 1 -(6-Cyclohexyl-4-(diethylamino)quinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 28 1 -(6-Cyclohexyl-4-(phenylamino)quinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 29 1 -(4-((2-Chlorophenyl)amino)-6-cyclohexylquinazolin-2-yl)-1 H- pyrazole-4-carboxylic acid.
• Example 31 1 -(6-Cyclohexyl-4-(4-fluoropiperidin-1 -yl)quinazolin-2-yl)-1 H-pyrazole- 4-carboxylic acid.
• Example 32 1 -(6-Cyclohexyl-4-(cyclopropylamino)quinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 33 1 -(6-Cyclohexyl-4-morpholinoquinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 34 1 -(6-Cyclohexyl-4-thiomorpholinoquinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 35 1 -(4-Cyanamido-6-cyclohexylquinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 36 1 -(4-(terf-Butylamino)-6-cyclohexylquinazolin-2-yl)-1 H-pyrazole-4 carboxylic acid.
• Example 37 1 -(4-(Azepan-1 -yl)-6-cyclohexylquinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 38 1 -(6-Cyclohexyl-4-(dimethylamino)quinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 39 1 -(6-Cyclohexyl-4-((cyclohexylmethyl)amino)quinazolin-2-yl)-1 H- pyrazole-4-carboxylic acid.
• Example 40 1 -(6-Cyclohexyl-4-(methylsulfonamido)quinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 41 1 -(4-(Dimethylamino)-6-phenylquinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 42 1 -(4-(Ethyl(methyl)amino)-6-phenylquinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 43 1 -(6-Phenyl-4-(pyrrolidin-1 -yl)quinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 44 1 -(6-Phenyl-4-(phenylamino)quinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 45 1 -(6-Phenyl-4-(piperidin-1 -yl)quinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 47 1 -(4-((2-Chlorophenyl)amino)-6-phenylquinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 49 1 -(4-((Cyclohexylmethyl)amino)-6-phenylquinazolin-2-yl)-1 H-pyrazole- 4-carboxylic acid.
• Example 50 1 -(4-Cyanamido-6-phenylquinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.
• Example 51 1 -(4-(Cyclopropylamino)-6-phenylquinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 52 1 -(4-(terf-Butylamino)-6-phenylquinazolin-2-yl)-1 H-pyrazole-4- carboxylic acid.
• Example 53 1 -(4-Amino-6-phenylquinazolin-2-yl)-1 H-pyrazole-4-carboxylic acid.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Epidemiology (AREA)
• Obesity (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Endocrinology (AREA)
• Vascular Medicine (AREA)
• Emergency Medicine (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Child & Adolescent Psychology (AREA)
• Physical Education & Sports Medicine (AREA)
• Urology & Nephrology (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (1)

Family

ID=44533176

Family Applications (1)

Country Status (6)

Cited By (3)

Families Citing this family (12)

Citations (9)

Family Cites Families (3)

• 2011
  • 2011-08-12 EP EP11749643.0A patent/EP2603502B1/en active Active
  • 2011-08-12 AU AU2011289230A patent/AU2011289230B2/en not_active Ceased
  • 2011-08-12 CN CN201180039665.8A patent/CN103068821B/zh active Active
  • 2011-08-12 JP JP2013524250A patent/JP5755741B2/ja active Active
  • 2011-08-12 US US13/816,747 patent/US8796263B2/en active Active
  • 2011-08-12 WO PCT/US2011/047626 patent/WO2012021830A1/en not_active Ceased
• 2014
  • 2014-06-24 US US14/313,892 patent/US9006251B2/en active Active - Reinstated
• 2015
  • 2015-03-26 US US14/670,352 patent/US9573940B2/en active Active
• 2017
  • 2017-02-17 US US15/436,596 patent/US10246442B2/en active Active - Reinstated
• 2019
  • 2019-04-01 US US16/371,400 patent/US10975062B2/en active Active

Patent Citations (9)

Non-Patent Citations (106)

Also Published As

Similar Documents

Legal Events